Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

After years of steady single-digit growth, the cardiac rhythm management market was jump-started this decade by the expansion of implantable cardioverter defibrillators and the development of cardiac resynchronization therapy devices. Those products drove annual growth rates above 20%. But in 2005, this growth came to a screeching halt due to product recalls and other safety issues. To address these concerns, CRM manufacturers are working with the FDA and the Heart Rhythm Society to restore the trust of both implanting physicians and the patient community.